We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: ID NOW Molecular Platform (Photo courtesy of Abbott)
Image: ID NOW Molecular Platform (Photo courtesy of Abbott)

Abbott (Lake Forest, IL, USA) participated in ECCMID 2022 where it highlighted its range of rapid diagnostic platforms that complement centralized RT-PCR testing as well as empowers labs to efficiently and cost-effectively extend their impact throughout hospitals.

Abbott’s product portfolio exhibited at ECCMID 2022 included ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The company’s ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing healthcare professionals to make effective clinical decisions sooner. Abbott demonstrated its Panbio COVID-19 Ag Rapid Test Device that can identify potentially contagious patients with or without symptoms in 15 minutes alongside its Panbio COVID-19 IgG/IgM Rapid Test Device for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood.

In addition, Abbott demonstrated its Afinion CRP rapid in vitro diagnostic test for the quantitative determination of C-reactive protein (CRP) in human blood in three minutes. Afinion CRP helps reduce diagnostic uncertainty and guides antibiotic decision-making during the patient’s visit. A significantly increased CRP result may indicate the need for immediate antibiotic treatment. CRP Point of care testing has been shown to reduce antibiotic prescribing by more than 60% if combined with communication training for general practitioners. The test runs on Abbott’s Afinion2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care. With the Afinion System, there’s no need to send patients to the lab or spend time tracking down their results.

Related Links:
Abbott 

New
Gold Supplier
ESR Analyzer
miniiSED™
New
AFP Detection Kit
Alpha-Fetoprotein (AFP) Rapid Test
New
Dengue IgG Test
Chorus Dengue IgG
New
3-in-1 Mixer
MixMate

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.